{
    "clinical_study": {
        "@rank": "29971", 
        "arm_group": [
            {
                "arm_group_label": "LDV/SOF 8 Week TN", 
                "arm_group_type": "Experimental", 
                "description": "Treatment-naive (TN) participants will receive LDV/SOF for 8 weeks."
            }, 
            {
                "arm_group_label": "LDV/SOF+RBV 8 Weeks", 
                "arm_group_type": "Experimental", 
                "description": "Treatment-naive participants will receive LDV/SOF plus RBV for 8 weeks."
            }, 
            {
                "arm_group_label": "LDV/SOF 12 Weeks TN", 
                "arm_group_type": "Experimental", 
                "description": "Treatment-naive participants will receive LDV/SOF for 12 weeks."
            }, 
            {
                "arm_group_label": "LDV/SOF 12 Weeks", 
                "arm_group_type": "Experimental", 
                "description": "Participants who were virologic failures following prior therapy with a protease-inhibitor (PI)+pegylated interferon (PEG)+RBV regimen received LDV/SOF for 12 weeks."
            }, 
            {
                "arm_group_label": "LDV/SOF+RBV 12 Weeks", 
                "arm_group_type": "Experimental", 
                "description": "Participants who were virologic failures following prior therapy with a PI+PEG+RBV regimen received LDV/SOF plus RBV for 12 weeks."
            }
        ], 
        "brief_summary": {
            "textblock": "This study is to evaluate the safety, tolerability and antiviral efficacy of ledipasvir\n      (formerly GS-5885)/sofosbuvir (LDV/SOF) fixed-dose combination (FDC) with or without\n      ribavirin (RBV) administered for 8 or 12 weeks of treatment in participants with chronic\n      genotype 1 hepatitis C virus (HCV) infection who are treatment-naive and for 12 weeks in\n      participants who had previously received a regimen containing a protease inhibitor for the\n      treatment of HCV."
        }, 
        "brief_title": "Safety and Efficacy of LDV/SOF Fixed-Dose Combination (FDC) \u00b1 Ribavirin in HCV Genotype 1 Subjects", 
        "completion_date": {
            "#text": "January 2014", 
            "@type": "Actual"
        }, 
        "condition": "Chronic Hepatitis C Virus", 
        "condition_browse": {
            "mesh_term": [
                "Hepatitis", 
                "Hepatitis A", 
                "Hepatitis, Chronic", 
                "Hepatitis C", 
                "Hepatitis C, Chronic"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Age equal to or greater than 18 years, with chronic genotype 1 HCV infection\n\n          -  HCV RNA equal to or greater than 10,000 IU/mL at Screening\n\n          -  Cirrhosis determination; a liver biopsy may be required\n\n          -  Screening laboratory values within defined thresholds\n\n          -  Use of two effective contraception methods if female of childbearing potential or\n             sexually active male\n\n        Exclusion Criteria:\n\n          -  Pregnant or nursing female or male with pregnant female partner\n\n          -  Current or prior history of clinical hepatic decompensation\n\n          -  Hepatocellular carcinoma (HCC) or other malignancy (with exception of certain\n             -resolved skin cancers)\n\n          -  Chronic use of systemic immunosuppressive agents\n\n          -  History of clinically significant illness or any other medical disorder that may\n             interfere with subject treatment, assessment or compliance with the protocol"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "100", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "November 10, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01726517", 
            "org_study_id": "GS-US-337-0118"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "LDV/SOF 8 Week TN", 
                    "LDV/SOF+RBV 8 Weeks", 
                    "LDV/SOF 12 Weeks TN", 
                    "LDV/SOF 12 Weeks", 
                    "LDV/SOF+RBV 12 Weeks"
                ], 
                "description": "Ledipasvir 90 mg/sofosbuvir 400 mg FDC tablet administered orally once daily", 
                "intervention_name": "LDV/SOF", 
                "intervention_type": "Drug", 
                "other_name": [
                    "GS-5885", 
                    "GS-7977", 
                    "PSI-7977"
                ]
            }, 
            {
                "arm_group_label": [
                    "LDV/SOF+RBV 8 Weeks", 
                    "LDV/SOF+RBV 12 Weeks"
                ], 
                "description": "Ribavirin (RBV) tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (< 75 kg = 1000 mg and \u2265 75 kg = 1200 mg)", 
                "intervention_name": "RBV", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Protease Inhibitors", 
                "HIV Protease Inhibitors", 
                "Ribavirin"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "HCV genotype 1 (GT-1)", 
            "HCV", 
            "Sustained Virologic Response", 
            "Direct Acting Antiviral", 
            "Combination Therapy", 
            "GS-7977", 
            "GS-5885", 
            "Ribavirin", 
            "Open Label", 
            "Sofosbuvir", 
            "Treatment-Na\u00efve", 
            "Protease Inhibitors", 
            "PI"
        ], 
        "lastchanged_date": "March 17, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "San Antonio", 
                    "country": "United States", 
                    "state": "Texas", 
                    "zip": "78215"
                }
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "5", 
        "official_title": "A Phase 2, Randomized, Open-Label Study of Sofosbuvir/GS-5885 Fixed-Dose Combination \u00b1 Ribavirin in Subjects With Chronic Genotype 1 HCV Infection", 
        "overall_official": {
            "affiliation": "Gilead Sciences", 
            "last_name": "Rob Hyland", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "July 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "description": "SVR12 is defined as HCV RNA < the lower limit of quantitation (LLOQ) 12 weeks following the last dose of study medication.", 
                "measure": "Proportion of participants with sustained virologic response 12 weeks after discontinuation of therapy (SVR12)", 
                "safety_issue": "No", 
                "time_frame": "Posttreatment Week 12"
            }, 
            {
                "measure": "Incidence of adverse events leading to permanent discontinuation of study drug(s)", 
                "safety_issue": "No", 
                "time_frame": "Baseline up to Week 12"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01726517"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "SVR2, SVR4, SVR8, and SVR24 is defined as HCV RNA < LLOQ at 2, 4, 8, and 24 weeks following the last dose of study medication, respectively.", 
                "measure": "Proportion of participants with sustained virologic response at 2, 4, 8, and 24 weeks after discontinuation of therapy (SVR2, SVR4, SVR8, and SVR24)", 
                "safety_issue": "No", 
                "time_frame": "Posttreatment Weeks 2, 4, 8, and 24"
            }, 
            {
                "description": "Viral breakthrough is defined as having confirmed detectable HCV RNA levels (HCV RNA > LLOQ) after having previously had undetectable HCV RNA levels (HCV RNA < LLOQ) while on treatment.", 
                "measure": "Proportion of participants experiencing viral breakthrough", 
                "safety_issue": "No", 
                "time_frame": "Baseline up to Week 12"
            }, 
            {
                "description": "Viral relapse is defined as having achieved undetectable HCV RNA levels (HCV RNA < LLOQ) at end of treatment, but did not achieve an SVR.", 
                "measure": "Proportion of participants experiencing viral relapse", 
                "safety_issue": "No", 
                "time_frame": "Up to Posttreatment Week 24"
            }
        ], 
        "source": "Gilead Sciences", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Gilead Sciences", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "October 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}